Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

被引:32
作者
Barnes, Theresa [1 ]
Moots, Robert [1 ]
机构
[1] Univ Liverpool, Acad Rheumatol, Liverpool L69 3BX, Merseyside, England
基金
英国医学研究理事会;
关键词
certolizumab pegol; TNF alpha; rheumatoid arthritis; nanomolecule;
D O I
10.2147/nano.2007.2.1.3
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Anti-TNF alpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNF alpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNF alpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 17 条
[1]  
Baker M, 2006, ANN RHEUM DIS, V65, P175
[2]  
BRENNAN FM, 1989, LANCET, V2, P244
[3]   True infliximab resistance in rheumatoid arthritis:: a role for lymphotoxin α? [J].
Buch, MH ;
Conaghan, PG ;
Quinn, MA ;
Bingham, SJ ;
Veale, D ;
Emery, P .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1344-1346
[4]   Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial [J].
Choy, EHS ;
Hazleman, B ;
Smith, M ;
Moss, K ;
Lisi, L ;
Scott, DGI ;
Patel, J ;
Sopwith, M ;
Isenberg, DA .
RHEUMATOLOGY, 2002, 41 (10) :1133-1137
[5]   LOCALIZATION OF TUMOR-NECROSIS-FACTOR-ALPHA IN SYNOVIAL TISSUES AND AT THE CARTILAGE PANNUS JUNCTION IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
CHU, CQ ;
FIELD, M ;
FELDMANN, M ;
MAINI, RN .
ARTHRITIS AND RHEUMATISM, 1991, 34 (09) :1125-1132
[6]  
Emery P, 2002, EUR LEAG RHEUM ANN C
[7]  
FELTS W, 1989, J RHEUMATOL, V16, P867
[8]  
Fossati G, 2006, ANN RHEUM DIS, V65, P455
[9]  
Fossati G, 2006, ANN RHEUM DIS, V65, P622
[10]  
Gramlick A, 2006, ANN RHEUM DIS, V65, P456